title: Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?
authors.affiliation: Division of Molecular Neuroimmunology, Department of Neurology, University Hospital Heidelberg, INF 400, D-69120 Heidelberg, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Lenhard
authors.forename: A
authors.initials: A
authors.lastname: Biller
authors.forename: W
authors.initials: W
authors.lastname: Mueller
authors.forename: I
authors.initials: I
authors.lastname: Metz
authors.forename: J
authors.initials: J
authors.lastname: Schönberger
authors.forename: B
authors.initials: B
authors.lastname: Wildemann
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000473:pathology; D000069442:Natalizumab; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab